TY - JOUR
T1 - Genomic Prediction of Antimicrobial Resistance
T2 - Ready or Not, Here It Comes!
AU - Ransom, Eric M.
AU - Potter, Robert F.
AU - Dantas, Gautam
AU - Burnham, Carey Ann D.
N1 - Publisher Copyright:
© 2020 American Association for Clinical Chemistry Inc.. All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - BACKGROUND: Next-generation sequencing (NGS) technologies are being used to predict antimicrobial resistance. The field is evolving rapidly and transitioning out of the research setting into clinical use. Clinical laboratories are evaluating the accuracy and utility of genomic resistance prediction, including methods for NGS, downstream bioinformatic pipeline components, and the clinical settings in which this type of testing should be offered. CONTENT: We describe genomic sequencing as it pertains to predicting antimicrobial resistance in clinical isolates and samples. We elaborate on current methodologies and workflows to perform this testing and summarize the current state of genomic resistance prediction in clinical settings. To highlight this aspect, we include 3 medically relevant microorganism exemplars: Mycobacterium tuberculosis, Staphylococcus aureus, and Neisseria gonorrhoeae. Last, we discuss the future of genomic-based resistance detection in clinical microbiology laboratories. SUMMARY: Antimicrobial resistance prediction by genomic approaches is in its infancy for routine patient care. Genomic approaches have already added value to the current diagnostic testing landscape in specific circumstances and will play an increasingly important role in diagnostic microbiology. Future advancements will shorten turnaround time, reduce costs, and improve our analysis and interpretation of clinically actionable results. VC American Association for Clinical Chemistry 2020. All rights reserved.
AB - BACKGROUND: Next-generation sequencing (NGS) technologies are being used to predict antimicrobial resistance. The field is evolving rapidly and transitioning out of the research setting into clinical use. Clinical laboratories are evaluating the accuracy and utility of genomic resistance prediction, including methods for NGS, downstream bioinformatic pipeline components, and the clinical settings in which this type of testing should be offered. CONTENT: We describe genomic sequencing as it pertains to predicting antimicrobial resistance in clinical isolates and samples. We elaborate on current methodologies and workflows to perform this testing and summarize the current state of genomic resistance prediction in clinical settings. To highlight this aspect, we include 3 medically relevant microorganism exemplars: Mycobacterium tuberculosis, Staphylococcus aureus, and Neisseria gonorrhoeae. Last, we discuss the future of genomic-based resistance detection in clinical microbiology laboratories. SUMMARY: Antimicrobial resistance prediction by genomic approaches is in its infancy for routine patient care. Genomic approaches have already added value to the current diagnostic testing landscape in specific circumstances and will play an increasingly important role in diagnostic microbiology. Future advancements will shorten turnaround time, reduce costs, and improve our analysis and interpretation of clinically actionable results. VC American Association for Clinical Chemistry 2020. All rights reserved.
UR - http://www.scopus.com/inward/record.url?scp=85092681882&partnerID=8YFLogxK
U2 - 10.1093/clinchem/hvaa172
DO - 10.1093/clinchem/hvaa172
M3 - Review article
C2 - 32918462
AN - SCOPUS:85092681882
SN - 0009-9147
VL - 66
SP - 1278
EP - 1289
JO - Clinical chemistry
JF - Clinical chemistry
IS - 10
ER -